CRIS Current Research Information System

COSMI, BENILDE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.211
AS - Asia 7.398
EU - Europa 4.686
SA - Sud America 390
AF - Africa 335
OC - Oceania 53
Continente sconosciuto - Info sul continente non disponibili 2
Totale 21.075
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.068
SG - Singapore 2.426
CN - Cina 1.889
VN - Vietnam 1.379
GB - Regno Unito 1.247
IT - Italia 775
DE - Germania 674
HK - Hong Kong 495
SE - Svezia 366
FR - Francia 365
IN - India 355
RU - Federazione Russa 301
BR - Brasile 274
UA - Ucraina 214
IE - Irlanda 180
KR - Corea 176
BD - Bangladesh 162
NL - Olanda 158
JP - Giappone 138
ZA - Sudafrica 124
EE - Estonia 92
FI - Finlandia 91
CA - Canada 69
PH - Filippine 66
ID - Indonesia 62
SC - Seychelles 57
CI - Costa d'Avorio 54
AR - Argentina 53
MX - Messico 48
AT - Austria 39
AU - Australia 36
TH - Thailandia 34
TW - Taiwan 29
EG - Egitto 28
IQ - Iraq 27
BE - Belgio 26
CH - Svizzera 26
PL - Polonia 26
SA - Arabia Saudita 25
CZ - Repubblica Ceca 21
GR - Grecia 20
JO - Giordania 18
MY - Malesia 18
PK - Pakistan 18
TR - Turchia 17
MA - Marocco 16
NZ - Nuova Zelanda 16
TG - Togo 14
UZ - Uzbekistan 14
CO - Colombia 13
ES - Italia 12
CL - Cile 11
BG - Bulgaria 10
EC - Ecuador 9
DZ - Algeria 8
KE - Kenya 8
PE - Perù 8
RO - Romania 8
LB - Libano 7
PY - Paraguay 7
TN - Tunisia 7
UY - Uruguay 7
AL - Albania 6
CR - Costa Rica 6
PS - Palestinian Territory 6
DK - Danimarca 5
NG - Nigeria 5
VE - Venezuela 5
AZ - Azerbaigian 4
BH - Bahrain 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
HN - Honduras 4
HR - Croazia 4
HU - Ungheria 4
IL - Israele 4
OM - Oman 4
AE - Emirati Arabi Uniti 3
KZ - Kazakistan 3
LT - Lituania 3
MM - Myanmar 3
NP - Nepal 3
TZ - Tanzania 3
BO - Bolivia 2
GE - Georgia 2
GT - Guatemala 2
KW - Kuwait 2
LK - Sri Lanka 2
LV - Lettonia 2
ML - Mali 2
NO - Norvegia 2
PA - Panama 2
PT - Portogallo 2
TT - Trinidad e Tobago 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BS - Bahamas 1
BZ - Belize 1
CG - Congo 1
Totale 21.056
Salva come PNG Salva come JPEG
Città #
Singapore 1.689
Southend 1.055
Fairfield 942
Santa Clara 701
Ashburn 680
Hong Kong 466
Woodbridge 403
Chandler 393
Seattle 388
San Jose 385
Wilmington 382
Houston 371
Hefei 357
Cambridge 324
Ho Chi Minh City 317
Princeton 309
Dong Ket 267
Beijing 249
Hanoi 242
Boardman 211
Ann Arbor 206
Dublin 177
Lauterbourg 154
Seoul 154
Bologna 122
Jacksonville 122
Nanjing 117
Tokyo 114
Westminster 114
Los Angeles 99
Padova 99
Berlin 93
Dallas 87
Council Bluffs 79
Buffalo 75
New York 74
Helsinki 72
Jinan 70
San Diego 64
Shenyang 63
Redondo Beach 61
Turin 61
Abidjan 53
Saint Petersburg 52
Milan 50
Da Nang 45
Changsha 42
Munich 42
São Paulo 42
Hebei 40
Dearborn 39
Frankfurt am Main 39
Redmond 37
Chicago 35
Nanchang 34
Bengaluru 33
Guangzhou 31
Rome 31
The Dalles 30
Des Moines 29
Haiphong 27
Shanghai 27
Brussels 26
London 26
Zhengzhou 26
Montreal 25
Mülheim 25
Hangzhou 23
Mexico City 23
Can Tho 22
Johannesburg 22
Tianjin 22
Jakarta 21
Falls Church 20
Moscow 20
Vienna 20
Al Mansurah 19
Amman 18
Bühl 18
Jiaxing 18
Nuremberg 18
Norwalk 17
Olalla 17
San Francisco 17
Baghdad 16
Bangkok 16
Bern 16
Fuzhou 16
Orem 16
Taiyuan 16
Toronto 16
Warsaw 16
Amsterdam 15
Atlanta 15
Biên Hòa 15
Brooklyn 15
Mahé 15
Lomé 14
Phoenix 14
Salt Lake City 14
Totale 13.874
Salva come PNG Salva come JPEG
Nome #
D-dimer in diagnosis and prevention of venous thrombosis: recent advances and their practical implications 552
A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). 310
Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis 260
Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. 212
Diagnostic Accuracy of a New d -Dimer Assay (Sclavo Auto d -Dimer) for Exclusion of Deep Vein Thrombosis in Symptomatic Outpatients 207
Padua Prediction Score and Hospital-Acquired Proximal and Isolated Distal Deep Vein Thrombosis in Symptomatic Patients 199
Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. 197
Age and gender specific cut-off values to improve the performance of D: -dimer assays to predict the risk of venous thromboembolism recurrence. 193
Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. 192
Enhancing stroke risk prediction in patients with transient ischemic attack: insights from a prospective cohort study implementing fast-track care 180
D-Dimer testing for predictive recurrence risk in venous thromboembolism: looking for a useful threshold: reply to a rebuttal. 180
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study 178
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study 174
D-dimer for the diagnosis of upper extremity deep and superficial venous thrombosis 172
Thrombotic burden, D-dimer levels and complete compression ultrasound for diagnosis of acute symptomatic deep vein thrombosis of the lower limbs. 170
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE 170
Age‐adjusted D‐dimer, clinical pre‐test probability‐adjusted D‐dimer, and whole leg ultrasound in ruling out suspected proximal and calf deep venous thrombosis 169
Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register 167
High plasma levels of factor VIII and risk of recurrence of venous thromboembolism 163
D-dimer, FVIII and thrombotic burden in the acute phase of deep vein thrombosis in relation to the risk of post-thrombotic syndrome 162
Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients 162
Capsular Warning Syndrome: Features, Risk Profile, and Prognosis in a Large Prospective TIA Cohort 161
Review: recombinant factor VIIa does not differ from placebo for prevention or treatment of bleeding in patients without hemophilia 160
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 159
D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis. 158
Inherited and acquired thrombophilic alterations in patients with superficial vein thrombosis of lower limbs 156
D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. 155
Incidence and clinical outcomes of heparin-induced thrombocytopenia: 11 year experience in a tertiary care university hospital 154
Anticoagulant therapy for symptomatic calf deep vein thrombosis 154
External validation of the DASH prediction rule: a retrospective cohort study 154
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations 153
Diagnosis of deep vein thrombosis. 152
Current management strategies and long-term clinical outcomes of upper extremity venous thrombosis 152
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study 150
Evaluation of a chemiluminescent immunoassay, the HemosIL AcuStar D-Dimer, in outpatients with clinically suspected deep venous thrombosis 149
Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). 148
Measurement of factor XIII (FXIII) activity by an automatic ammonia release assay using iodoacetamide blank-procedure: no more overestimation in the low activity range and better detection of severe FXIII deficiencies 147
D-dimer and reduced dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study. 146
Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis. 146
Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH 146
Thrombin generation and intracranial atherosclerotic disease in patients with a transient ischaemic attack 145
D-dimer use for deep venous thrombosis exclusion in elderly patients: a comparative analysis of three different approaches to establish cut-off values for an assay with results expressed in D-dimer units 145
Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. 144
Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication 144
Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study. 143
The incidence of heparin-induced thrombocytopenia in patients treated with low molecular weight heparin for superficial vein thrombosis 143
Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: A prospective multicenter study 142
Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 141
A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms 141
Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. 140
Predicting the risk of recurrence of venous thromboembolism. 140
The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers--two independent studies. 140
Ultrasound Characteristics of Calf Deep Vein Thrombosis and Residual Vein Obstruction After Low Molecular Weight Heparin Treatment 140
Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study. 140
Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia 139
D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A post-hoc analysis of the Prolong extension study. 139
Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans 138
Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. 137
D-dimer and risk of venous thromboembolism recurrence: Comparison of two studies with similar designs but different laboratory and clinical results 136
Malattia tromboembolica polmonare 135
An update on the pharmaceutical management of thrombosis 135
Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 135
Is there a role for intervention radiology for the treatment of lower limb deep vein thrombosis in the era of direct oral anticoagulants? A comprehensive review 135
The influence of VKORC1 3730 G > A polymorphism on warfarin dose: reply. 134
Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. 132
Gynecological Cancer and Venous Thromboembolism: A Narrative Review to Increase Awareness and Improve Risk Assessment and Prevention 131
Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. 130
Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. 129
D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. 129
Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants 129
ACP Journal Club. Review: Low-molecular-weight heparin reduces risk for venous thromboembolism in adults with leg immobilization. 127
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. 127
D-dimer, oral anticoagulation, and venous thromboembolism recurrence 126
Is there a role for oral anticoagulant therapy in patients with peripheral arterial disease? 125
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. 124
Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of a portable prothrombin time monitor (COAGUCHECK) 124
Inappropriate Underdosing of Direct Oral Anticoagulants in Atrial Fibrillation Patients: Results from the START2-AF Registry 123
The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: A prospective cohort study (the PROLONG PLUS study). 123
Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. 123
The Wells rule and D-dimer for the diagnosis of isolated distal deep vein thrombosis 122
Risks factors for highly unstable response to oral anticoagulation: a case-control study. 122
Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis 122
Extended treatment for venous thromboembolism: how long is long enough? 121
ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent. 121
Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therap 121
Heparin-induced thrombocytopenia: new insights into the immune response 119
Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism. 118
Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor. 118
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 118
D-dimer testing to determine the duration of anticoagulation therapy. 118
Value of D-dimer testing to decide duration of anticoagulation after deep vein thrombosis: yes. 118
DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register 118
Whole-Arm Ultrasound for Suspected Upper-Extremity Deep Venous Thrombosis in Outpatients Reply 117
Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register 117
Current management of heparin-induced thrombocytopenia 116
Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia 116
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 114
Whole-Arm Ultrasound to Rule Out Suspected Upper-Extremity Deep Venous Thrombosis in Outpatients 113
Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-Art. 112
Duration of anticoagulation after isolated pulmonary embolism 112
Totale 14.995
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.375
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.375
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021402 0 0 0 0 0 0 0 0 0 0 0 402
2021/20222.051 205 95 177 116 246 111 63 207 87 97 289 358
2022/20232.016 261 281 117 275 111 162 59 116 283 93 172 86
2023/2024427 36 97 44 30 28 20 20 34 17 41 27 33
2024/20253.600 82 533 166 225 943 173 245 48 106 234 173 672
2025/20267.570 519 753 777 547 1.061 484 696 267 1.191 591 442 242
Totale 21.549